Younghee Kim
Family · Goodlettsville, TNNPI 1598883720
Payments from drug & device makers
Across 109 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$396
- Johnson & Johnson$314
- AstraZeneca$305
- Exact Sciences$175
- Pfizer$149
- Novo Nordisk$138
- plus $490 from 11 others
What the payments were for
- Food & beverage$1,968100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $396 |
| Johnson & Johnson(2 entities) | 11 | $314 |
| AstraZeneca | 19 | $305 |
| Exact Sciences | 11 | $175 |
| Pfizer | 7 | $149 |
| Novo Nordisk | 8 | $138 |
| Otsuka America Pharmaceutical, Inc. | 6 | $115 |
| Lilly USA, LLC | 7 | $99 |
| Boehringer Ingelheim | 4 | $69 |
| Eisai Inc. | 3 | $47 |
| Astellas Pharma US Inc | 2 | $34 |
| Novartis | 2 | $31 |
| Merck | 2 | $25 |
| Abbott | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,968 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 24 | $42,446 |
| RybelsusSemaglutide | 13 | $25,955 |
| EliquisApixaban | 14 | $22,885 |
| MounjaroTirzepatide | 16 | $21,177 |
| XareltoRivaroxaban | 12 | $20,935 |
| TradjentaLinagliptin | 21 | $19,262 |
| FarxigaDapagliflozin Propanediol | 25 | $14,714 |
| Ondansetron Hcl | 18 | $6,627 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $5,262 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,630 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 88 | $1,543 |
| Rosuvastatin Calcium | 87 | $1,490 |
| Tizanidine Hcl | 31 | $1,410 |
| Gabapentin | 83 | $1,360 |
| Losartan Potassium | 75 | $1,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $138 | $68,40037 claims |
| PfizerEliquis | $149 | $22,88514 claims |
| Lilly USA, LLCMounjaro | $99 | $21,17716 claims |
| Johnson & JohnsonXarelto | $314 | $20,93512 claims |
| Boehringer IngelheimTradjenta | $69 | $19,26221 claims |
| AstraZenecaFarxiga | $305 | $14,71425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.
Other family in Goodlettsville
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.